1. Home
  2. IRWD vs EOLS Comparison

IRWD vs EOLS Comparison

Compare IRWD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.32

Market Cap

520.6M

Sector

Health Care

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$6.70

Market Cap

444.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRWD
EOLS
Founded
1998
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
520.6M
444.0M
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
IRWD
EOLS
Price
$3.32
$6.70
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$5.34
$20.50
AVG Volume (30 Days)
2.3M
843.1K
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.18
N/A
Revenue
$338,987,000.00
$285,823,000.00
Revenue This Year
N/A
$14.24
Revenue Next Year
$4.01
$21.77
P/E Ratio
$19.03
N/A
Revenue Growth
N/A
15.10
52 Week Low
$0.53
$5.71
52 Week High
$4.78
$17.12

Technical Indicators

Market Signals
Indicator
IRWD
EOLS
Relative Strength Index (RSI) 55.41 43.99
Support Level $3.11 $6.57
Resistance Level $3.39 $6.93
Average True Range (ATR) 0.20 0.23
MACD -0.06 -0.05
Stochastic Oscillator 36.36 16.23

Price Performance

Historical Comparison
IRWD
EOLS

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: